About this Research Topic
Within this Research Topic, we aim to provide an overview on the recent preclinical and clinical activities of targeting KRAS in NSCLC, including ongoing efforts to improve the outcome by targeting guanine nucleotide exchange factors (GEFs), by inhibiting the active (GTP-bond) state, by combining treatment with other targeted approaches or treatment modalities, and by focusing on the non-p.G12C subgroups.
This Research Topic will be focused on the progress and controversies in translational and clinical research on KRAS targeting in NSCLC. We welcome Original Research, Review articles, Perspective and Opinion articles, and unique Case Reports, which are aimed at deepening the translational/biological/genomics/clinical landscape of patients affected by KRAS mutated NSCLC, exploring epidemiology, diagnosis, prognosis, drug development, resistance mechanisms, as well as rationale for combination.
Keywords: Mutations, Precision Medicine, Targeted Therapy, Oncology, Lung Cancer, KRAS
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.